Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHammerson Regulatory News (HMSO)

Share Price Information for Hammerson (HMSO)

Share Price is delayed by 15 minutes
Get Live Data
340.80    -2.20 (-0.64%)
Bid:
340.60
Ask:
341.20
Spread: 0.60 (0.176%)
Market Cap: £1.81b
HMSO Live PriceLast checked at - London Stock Exchange

Intraday Hammerson Share Chart

Publication of Final Terms

16 Oct 2025 13:00

RNS Number : 7020D
Hammerson PLC
16 October 2025
 

HAMMERSON PLC

16 October 2025

Hammerson plc

PUBLICATION OF FINAL TERMS

The Final Terms dated 13 October 2025 relating to the issuance by Hammerson plc (the "Issuer") of EUR 350 million 3.500 per. cent notes due 2032 (the "Notes") are available for viewing.

The Final Terms will shortly be made available on the Issuer's website. Please paste the following URLs into the address bar of the browser:

https://www.hammerson.com/investors/debt-investors

A copy of the Final Terms has been submitted to the National Storage Mechanism and is available for inspection at: 

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Notes have been issued under the £5,000,000,000 Euro Medium Term Note Programme of the Issuer (the "Programme").

The Final Terms should be read and construed in conjunction with the prospectus dated 15 April 2025, as supplemented by the prospectus supplement dated 4 September 2025 (the "Prospectus").

Enquiries

Richard Sharp, Director of Treasury and Insurance Tel: + 44 (0) 207 887 1119 E:richard.sharp@hammerson.com

Hammerson Investor ContactsJosh Warren, Director of Group Performance and Investor Relations T: +44 (0) 20 7887 1053 E: josh.warren@hammerson.com

MHP for Hammerson Media Ollie Hoare and Charles HirstT: +44 (0)20 3128 8100 E: Hammerson@mhpgroup.com

DISCLAIMER - INTENDED ADDRESSEES

EU MiFID II professionals/ECPs only/No EEA PRIIPs KID

UK MiFIR professionals/ECPs only/No UK PRIIPs KID

Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (as specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus, you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.

In particular, neither this announcement nor the Prospectus shall constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction.

The Notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any United States ("U.S.") state securities laws and, unless so registered, may not be offered or sold or (in the case of Notes in bearer form) delivered within the United States or to, or for the account or benefit of, U.S. persons as defined in Regulation S under the Securities Act ("Regulation S") except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act and applicable U.S. state securities laws.

Your right to access this service is conditional upon complying with the above requirements.

 

The announcement above has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTEAFEKFAASFFA
Date   Source Headline
8th Jun 202612:15 pmRNSAdmission to Trading
8th Jun 202611:00 amRNSDirector/PDMR Shareholding
5th Jun 20268:00 amRNSPublication of Final Terms
2nd Jun 20267:00 amRNSSuccessful pricing of 5-year EUR350m bond
29th May 20263:45 pmRNSHolding(s) in Company
26th May 202610:00 amRNSResults of Dividend Reinvestment Plan
22nd May 20264:15 pmRNSDirector/PDMR Shareholding
19th May 20262:00 pmRNSDirector/PDMR Shareholding
15th May 202612:30 pmRNSDirector/PDMR Shareholding
14th May 20263:00 pmRNSDirector/PDMR Shareholding
30th Apr 20264:30 pmRNSTotal Voting Rights
30th Apr 202611:15 amRNSResult of AGM
30th Apr 20267:00 amRNSHammerson CFO to retire
29th Apr 20267:00 amRNSHolding(s) in Company
28th Apr 20263:00 pmRNSDirector/PDMR Shareholding
24th Apr 20261:30 pmRNSEMTN Programme: Publication of Base Prospectus
24th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSHolding(s) in Company
8th Apr 20264:00 pmRNSDirector/PDMR Shareholding
7th Apr 202612:45 pmRNSTotal Voting Rights and Capital
30th Mar 202610:00 amRNSDirector/PDMR Shareholding
26th Mar 202611:00 amRNSAnnual Report and Notice of Annual General Meeting
19th Mar 20262:00 pmRNSDirector/PDMR Shareholding
17th Mar 202610:00 amRNSDirector/PDMR Shareholding
17th Mar 20269:00 amRNSDividend Currency Conversion Announcement
25th Feb 20267:01 amRNSDividend Declaration
25th Feb 20267:00 amRNSFinal Results
6th Feb 20267:00 amRNSDirectorate change
28th Jan 20269:00 amRNSNotice of Results
20th Jan 20263:30 pmRNSHolding(s) in Company
22nd Dec 202511:30 amRNSDirector/PDMR Shareholding
22nd Dec 20259:30 amRNSDirector/PDMR Shareholding
15th Dec 20253:00 pmRNSDirector/PDMR Shareholding
11th Dec 20252:15 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSDirectorate change
21st Nov 20257:00 amRNSAcquisition of The Oracle and Trading Update
13th Nov 20251:45 pmRNSDirector/PDMR Shareholding
31st Oct 20257:45 amRNSResults of Dividend Reinvestment Plan
28th Oct 20251:00 pmRNSDirector/PDMR Shareholding
24th Oct 20254:00 pmRNSDirector/PDMR Shareholding
23rd Oct 202511:00 amRNSDirector/PDMR Shareholding
22nd Oct 20254:30 pmRNSDirector/PDMR Shareholding
21st Oct 202512:00 pmRNSDirector/PDMR Shareholding
16th Oct 20251:00 pmRNSPublication of Final Terms
9th Oct 20257:00 amRNSBond Pricing, Guidance & Operational Update
25th Sep 20254:30 pmRNSHolding(s) in Company
19th Sep 20253:30 pmRNSDirector/PDMR Shareholding
11th Sep 20254:45 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNSAppointment of Rob Wilkinson as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.